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Animal agriculture is being transformed by rapid advances in biotechnology—a term that
encompasses a variety of technologies, including genetic engineering (GE), genetic modification,
transgenics, recombinant DNA techniques, and cloning, among others. Producers are interested in
the application of biotechnology to improve productivity, consistency, and quality; to introduce
new food, fiber, and medical products; and to protect the environment. Potential human health
applications of transgenic animals include producing biopharmaceuticals and generating organs,
tissues, and cells for xenotransplantation. Criticisms of such applications involve issues ranging
from food safety and social resistance to potential negative impacts on animal welfare and on
ecosystems. Questions also have arisen about the adequacy of the current regulatory structure to
assess and manage any risks created by these technologies.
On January 15, 2009, the U.S. Food and Drug Administration (FDA) released final guidance on
how it is to regulate GE animals and products. FDA is to do so under its existing statutory
authority and regulations. Generally, GE-derived foods, for example, are to be regulated like nonGE foods; if their composition does not differ from their conventional counterparts, they will not
have to be labeled. Nonetheless, developers of GE animals and of GE-derived products must gain
FDA pre-market approval.
On February 6, 2009, the FDA announced the first approval of a drug from a GE animal. The
drug is a human anti-clotting agent produced in the milk of transgenic goats.
Although animal biotechnology involves many techniques other than cloning, this latter
technology has attracted widespread attention. A final risk assessment and industry guidance on
the safety of meat and milk from cloned cattle, pigs, and goats and their offspring were released
January 15, 2008, by FDA. The documents generally echoed the FDA’s December 28, 2006, draft
risk assessment, which found that such products are as safe to eat as those of conventionally bred
animals. The FDA also concluded that cloning poses the same risks to animal health as those
found in animals created through other assisted reproductive technologies—although the
frequency of such problems is higher in cloning. (Scientists stress that cloning is an assisted
reproduction technique that does not involve any transfer or alteration of genes through GE.) The
agency said it was no longer asking industry to refrain voluntarily from marketing the products of
cloned animals and their offspring, although the U.S. Department of Agriculture (USDA) did ask
that it be continued for products from clones (but not from the offspring of clones).
The Senate-passed version of the 2007-2008 farm bill would have delayed the FDA final risk
assessment and continued the marketing moratorium until completion of newly mandated studies
on the safety and on the market impacts of introducing such products. This delay was not retained
in the enacted version of the bill (P.L. 110-234). Bills on animal cloning in the 110th Congress
would have required all food from cloned animals or their offspring to be labeled, and prohibited
food from cloned animals from being labeled as organic. These and other bills on cloning or other
regulation of animal biotechnology could be offered in the 111th Congress.
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The U.S. Food and Drug Administration (FDA) released two recent documents that renewed
public and congressional interest in animal biotechnology in general and animal cloning in
particular. On January 15, 2009, the agency released final guidance representing its current
thinking on the regulation of genetically engineered (GE) animals for food or drugs. FDA did so
under its existing statutory authority and regulations.1 A year earlier, on January 15, 2008, FDA
had unveiled its final risk assessment and industry guidance on the safety of milk and meat from
cloned animals and their offspring. The FDA found that, generally, meat and milk products from
cattle, pigs, and goats are as safe as products from their non-cloned counterparts.2
Still, some in the United States remain concerned about the safety and other impacts of GE
animals and of animal cloning, and they continue to advocate a cautious approach to
commercialization of such products. Outside of the United States, animal biotechnology,
including both GE and cloning, is the focus of ongoing regulatory, policy and scientific
discussions within the European Union (EU) as well as within the international organization for
animal health, known by its French acronym, the OIE. (Cloning by itself is not considered to be
genetic engineering; see discussion later in this report).
Biotechnology is a broadly defined term of relatively recent origin describing the range of
modern knowledge, applications, and techniques underlying advances in many fields, notably
health care and agriculture. Animal biotechnology has been defined as “that set of techniques by
which living creatures are modified for the benefit of humans and other animals.”3 By its very
nature, agricultural development is the history of humans modifying plants and animals to
maximize desirable traits. For example, domestication and selective breeding of animals date
back many thousands of years. Artificial insemination of livestock, notably dairy cattle, is a more
recent technology, first finding wide commercial acceptance in the 1950s.
Discovery of the genetic code in the 1950s gave birth to modern techniques of biotechnology.
One of the first commercial products of this new biotechnology in animal agriculture was bovine
somatotropin (bST), a naturally occurring metabolic modifier that is now being manufactured in
larger quantities through the use of recombinant DNA technology. Manufactured bST came onto
1

CVM, FDA, Guidance for Industry: Regulation of Genetically Engineered Animals Containing Heritable rDNA
Constructs. The guidance can be accessed through the FDA website at http://www.fda.gov/OHRMS/DOCKETS/98fr/
FDA-2008-D-0394-gdl.pdf.
2
FDA documents were posted on the Internet at http://www.fda.gov/cvm/cloning.htm on January 15, 2008.
3
National Research Council (NRC), Animal Biotechnology: Science-Based Concerns, (Washington, DC, National
Academy Press, 2002). (Hereafter cited as NRC, Animal Biotechnology.) Unless noted, this CRS report is based on
material in that document and the following additional sources: Institute of Medicine (IOM) and NRC, Safety of
Genetically Engineered Foods: Approaches to Assessing Unintended Health Effects (Washington, DC, National
Academy Press, 2004). (Hereafter cited as IOM-NRC, Safety of Genetically Engineered Food.); Council for
Agricultural Science and Technology (CAST), Biotechnology in Animal Agriculture: An Overview (Issue Paper 23)
(Washington, DC, February 2003). (Hereafter cited as CAST, Animal Agriculture.); Pew Initiative on Food and
Biotechnology, Issues in the Regulation of Genetically Engineered Plants and Animals, (Washington, DC, Pew
Initiative April 2004. See http://pewagbiotech.org/research/regulation/.) (Hereafter cited as Pew, Issues in Regulation.);
Pew Initiative on Food and Biotechnology, Post-Market Oversight of Biotech Foods (Washington, DC, Pew Initiative
April 2003) (and other Pew materials); information accessed through the websites of the Biotechnology Industry
Organization at http://www.bio.org/; the Center for Food Safety, at http://www.centerforfoodsafety.org/; the Union of
Concerned Scientists, at http://www.ucsusa.org/; and the Consumer Federation of America, at
http://www.consumerfed.org/.
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the market in 1994 and is now administered to as many as half of all U.S. dairy cattle to increase
per-cow milk output. Although bST is being used commercially in approximately 20 countries, it
is banned in the European Union (EU).
The first U.S. approval of a commercial product from a GE animal is for the drug ATryn, an anticlotting agent being produced in the milk of transgenic goats. The FDA announced its approval
on February 6, 2009.
Other developments include pigs that have been engineered for increased sow milk output to
produce faster-growing piglets. Cloned cattle also have been developed to resist mastitis, and
transgenic salmon with enhanced growth characteristics are under regulatory consideration for
possible commercialization. Output traits such as drugs recovered from animal milk
(“pharming”), milk that lacks allergenic proteins, and animal organs for human transplant
(xenotransplantation) that resist rejection are other contemporary objectives of animal
biotechnology research. In March 2006, researchers at the University of Missouri announced the
creation of transgenic pigs whose tissue contains omega-3 fatty acids.4 The consumption of
omega-3 fatty acids, found primarily in fish, has been linked to lowered incidence of heart disease
in humans. Similar research is also under way to produce omega-3 fatty acids in cow’s milk and
in chicken eggs.
This report describes several scientifically emerging animal biotechnologies that are raising a
variety of questions concerning risks to humans, animals, and the environment, as well as ethical
concerns. The report examines applications of the technologies and discusses major issues that
may arise. Consumers, agricultural producers, the biotechnology industry, and federal regulatory
bodies are debating the relative costs and benefits of these technologies. As technologies move
toward commercialization, Congress is being asked to examine these issues and possibly to refine
the current federal regulatory structure governing the technologies and their agricultural products.

ȱȱ
Given the breadth of the term “animal biotechnology,” one might reasonably define it to include
thousands of years of humans selectively breeding animals: observing desirable animal traits and
attempting to breed those traits into successive lines of animals. One of the first modern forms of
assisted reproductive technology (ART) was artificial insemination (AI). AI has been long
established as a technological advance in traditional selective breeding and an important adjunct
to the development of modern industrial animal production, especially in dairy and poultry. AI
was adopted by producers and accepted by the public with virtually no controversy. For example,
more than 70% of all U.S.-bred Holstein cows, by far the most widely used milk producers, are
artificially inseminated.5 Estrus synchronization, which improves the efficiency of AI by more
accurately controlling when a female was in heat, is also an important animal biotechnology.
With the development in the 1970s and patenting in the 1980s of recombinant DNA techniques,
and the subsequent analysis of genes, their resulting proteins, and the role played by the proteins
in animal biochemical processes (functional genomics), modern biotechnology is increasingly
4

New York Times, March 27, 2006.
FDA, “A Primer on Cloning and Its Use in Livestock Operations,” at http://www.fda.gov/cvm/
CloningRA_Primer.htm.

5
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equipped with a set of sophisticated tools holding the promise of transforming the selective
breeding of animals. The range of new techniques and technologies could transform animal
biotechnology in ways that plant biotechnology was transformed in the 1980s and 1990s.
Modern animal biotechnology is developing against the background of public experience with
plant biotechnology, and controversy over the technologies may be a continuing feature of animal
biotechnology development, not least because of the closer connection between humans and some
animals and the belief that techniques developed for animals are only a step away from
application to humans. Some of the better known animal biotechnologies follow. A number of
them are types of assisted reproductive technology (ART).

¢ȱȱ
After AI and estrus synchronization, embryo transfer (ET) is the third most commonly used
biotechnology. In ET, a donor cow of superior breeding is chemically induced to superovulate.
The eggs are then fertilized within the donor, the embryo develops and is then removed and
implanted in a recipient cow. Between removal and implantation, embryos may be frozen for
safekeeping. Because of the relatively high costs, ET is used mostly within registered cowherds.

ȱ
A prominent area of contemporary animal biotechnology research is the development of
transgenic animals through genetic engineering (GE) technology.6 Transgenic animals are
produced by introducing an isolated DNA fragment into an embryo so that the resulting animal
will express a desired trait. Transgenic animals may be generated by the introduction of foreign
DNA obtained through animals of the same species, animals of different species, microbes,
humans, cells, and in vitro nucleic acid synthesis. The only currently routine use of transgenic
animals, primarily mice, is in the area of human disease research. The anti-clotting agent in goat
milk is the first such application to be approved by the FDA. Potential agricultural applications
for such genetic engineering, however, include improved feed use and faster growth; more
resistance to disease; meat that is leaner or that has more of some other desirable quality; and
possibly even animal waste that is more environmentally benign. Table 1 provides examples of
various objectives of animal biotechnology involving genetic modification.

ȱȱ£ȱ
With in vitro fertilization (IVF), a technician removes unfertilized eggs (oocytes) from the donor
cow’s ovaries, usually recovering 6-8 useable oocytes. The oocytes mature in an incubator and
are fertilized with sperm. The resulting zygotes incubate and develop in the laboratory before
being placed into the recipient cow. While IVF can produce many fertilized embryos, the added
expense of ET makes the procedure prohibitive in most cases.

6
Genetic engineering (GE) here refers to the use of molecular biology to alter cells by inserting or removing genes. GE
is a form of genetic modification (GM), which refers more broadly to the practices of altering an organism’s genetic
composition by both GE and non-GE methods.
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The dairy industry prefers heifers and the beef industry prefers bulls. Embryo sexing methods in
cattle have been developed using a bovine Y-chromosome probe. Technicians remove a few cells
from the embryo and assess the DNA in these cells for the presence of a Y-chromosome. Presence
of a Y-chromosome determines the embryo is male. Research is also developing in sperm sexing
technology.

Purpose

Table 1. Agricultural Applications of Animal Transgenics
Animal model

Transgenic source

Altered milk composition (higher protein)

Cattle, swine,
rabbits, sheep
Cattle

Anti-clotting drug production in milka
“Biosteel” production in milkb
Reduced phosphorus in swine feces
Increased wool production

Goat
Goat
Swine
Sheep

Disease resistance

Swine, sheep,
rabbit

Xenotransplantation: Developing animal organs
for human transplantation

Swine

Growth hormones/factors: Human, Bovine,
Porcine, Rat, Chicken
Extra copies of casein genes; disruption of
lactoglobulin gene: Cow
Human antithrombin gene
Spider
Phytase gene; Bacteria
Cysteine synthesis gene: Bacteria
Growth factor: Sheep
Monoclonal antibodies: Mouse
Viral envelope genes: Sheep
CD55 (DAF-decay activating factor: Human
CD59: Human

Faster growth/leaner meat

GeneWatch UK, April 2002.
a. FDA approval for commercial use announced February 6, 2009. Source: FDA.
b. “Biosteel” is the trade name for spider web material intended to be produced in the milk of a transgenic
goat. Said to be twenty times stronger than steel, “Biosteel” has an envisioned breaking strength of about
300,000 pounds per square inch and could produce microscopically fine, super strong fibers for industrial
use.
Source:

ȱ
Cloning, discussed at greater length later in this report, is a biotechnology developing rapidly and
with significant public controversy. Most people think of cloning as the creation of an organism
that is genetically identical to another one. However, scientists use the term more broadly, to refer
to production not only of such organisms but also of genetically identical cells, and to replication
of DNA and other molecules. It also refers to a form of reproduction found naturally in many
single-celled organisms, as well as plants and animals. Those differences in meaning and usage
have caused some confusion in public debate about cloning, where the main area of controversy
relates to artificial cloning involving higher organisms, including humans.7

7

See CRS Report RL31358, Human Cloning, by Judith A. Johnson and Erin D. Williams.
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This is a technique where researchers inactivate, or “knock out,” a gene by replacing it or
disrupting it with an artificial piece of DNA in order to determine what that particular gene
does—e.g., cause or protect against some disease, alter metabolism, and so forth. A knockout
mouse is a laboratory mouse subjected to this technology.8

ȱȱȱ
The basic federal guidance for regulating the products of agricultural biotechnology is the
Coordinated Framework for Regulation of Biotechnology (51 Fed. Reg. 23302), published in
1986 by the White House Office of Science and Technology Policy (OSTP). A key principle has
been that GE products should continue to be regulated according to their characteristics and
unique features, not their methods of production, that is, whether or not they were created through
biotechnology. The framework provides a regulatory approach intended to ensure the safety of
biotechnology research and products, using existing statutory authority and previous policy
experience.
Some newer applications of biotechnology did not exist when the current regulatory framework
was enunciated. The NRC animal biotechnology report concluded that this regulatory regime
“might not be adequate to address unique problems and characteristics associated with animal
biotechnologies” and that federal agency responsibilities are not clear.9

ȱȱȱȱǻǼȱ
Within the Department of Health and Human Services (HHS), the FDA regulates food, animal
feed ingredients, and human and animal drugs, primarily under the Federal Food, Drug, and
Cosmetic Act (FFDCA; 21 U.S.C. §301 et seq.). The FDA has stated that most—although
probably not all—gene-based modifications of animals for production or therapeutic claims fall
within the purview of the agency’s Center for Veterinary Medicine (CVM), which regulates them
under the FFDCA as new animal drugs. A new animal drug (NAD) must be approved by the
agency after it is demonstrated to be safe to man and animals, as well as being effective.
Regulation of transgenic animals as NADs, however, suggests to some observers (e.g., the Center
for Food Safety, Union of Concerned Scientists) the inherent weakness of existing regulatory
structures to respond adequately to the complexities that arise with animal biotechnology
innovations.10
Primarily under the FFDCA, FDA’s Center for Food Safety and Applied Nutrition (CFSAN) is
responsible for assuring that domestic and imported foods are safe and properly labeled.
Generally, FDA does not review new foods themselves for safety before they enter commerce but
8

National Institutes of Health, National Human Genome Research Institute, “Knockout Mice,” accessed January 21,
2009, at http://www.genome.gov/12514551.
9
NRC, Animal Biotechnology, p. 14.
10
See Center for Food Safety website, at http://www.centerforfoodsafety.org/geneticall7.cfm; and the Union of
Concerned Scientists website, at http://www.ucsusa.org/food_and_agriculture/. Also see discussion of FDA’s guidance
for industry, later in this section.
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does have enforcement authority to act if it finds foods that are adulterated under the act. All food
additives, whether or not introduced through biotechnology, must receive FDA safety approval
before they can be sold; the exception to pre-market approval are those on a list the FDA has
determined to be “generally recognized as safe” (GRAS).11 12
Sections of the FFDCA and of the Public Health Service Act (42 U.S.C. §262 et seq.) provide the
authorities for FDA’s Center for Drug Evaluation and Research and Center for Biologics
Evaluation and Research to regulate the safety and effectiveness of human drugs and other
medical products, including those produced by GM animals. Under these laws, the FDA requires
pre-market review and licensing of such products, and requires that their production conditions
ensure purity and potency.13

FDA Approval of Drug in Goat Milk

The FDA’s approval of the drug ATryn was the first of a commercially available product from a GE animal. FDA
announced its decision on February 6, 2009, and published the final rule as a new animal drug application (NADA) in
the February 11, 2009, Federal Register (74 Fed. Reg. 6823). The drug is an anticoagulant for the treatment of human
patients with hereditary antithrombin deficiency; it is derived from the milk of goats bred with the introduction of an
rDNA construct directing the expression of the human gene antithrombin. The milk is being produced by a herd of
GE dairy goats in Massachusetts, which, the agency stated, had not demonstrated any negative health problems over
seven generations. Controls are in place to ensure that no milk or meat from the goats will enter the food or feed
supply, according to FDA. Biotechnology industry officials expressed their support for the approval; a leading animal
activist group, the Humane Society of the United States, countered that the action “seems to perpetuate the notion
of [animals] being merely tools for human use rather than sentient creatures.”

ȱ ȱȱ ȱȱ
On January 15, 2009, FDA’s CVM released its industry guidance on how it plans to regulate GE
animals.14 This final document hews closely (with a few modifications) to the draft version that
FDA published on September 18, 2008. The final document asserts that FDA’s authority to
regulate GE animals comes under the new animal drug provisions of the FFDCA. A drug is
defined by the act, in part, as “intended to affect the structure or any function in the body of man
11
The FDA, as of early 2009, has not granted approval for any human foods from transgenic (or cloned) animals,
although a “very limited number have been approved for rendering into animal feed components.” The only FDAapproved product of biotechnology in wide commercial use is bST, and an application is pending for a GE salmon.
(Questions and Answers about Transgenic Fish, at http://www.fda.gov/cvm/transgen.htm).
12
Also see CRS Report RL34247, Federal Regulation of Substances Generally Recognized As Safe (GRAS) and the
Use of Carbon Monoxide in Packaging for Meat and Fish, by Vanessa K. Burrows and Cynthia Brougher.
13
NRC, Animal Biotechnology, p. 163. At a January 9, 2009 meeting, the FDA Blood Products Advisory Committee
ruled that a new drug to prevent clots in humans, recombinant human antithrombin III produced in the milk of GE
goats, is safe and effective. The FDA could make a final regulatory decision to approve the license application of its
developer, GTC Biotherapeutics, soon. Source: “FDA issues final guidance to industry on transgenic animals,” Food
Chemical News, January 19, 2009.
14
Guidance for Industry: Regulation of Genetically Engineered Animals Containing Heritable rDNA Constructs. FDA
noted that much of the new guidance will be relevant also to non-heritable rDNA constructs (such as modifications
intended for gene therapy); a separate guidance for non-heritable constructs might come later.
The agency states at the outset: “This guidance represents the Food and Drug Administration’s (FDA’s) current
thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or
the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and
regulations.”
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or other animals.” Also, part of the FFDCA definition of “new animal drug” is one intended for
use in animals that is not generally recognized as safe and effective for use under the conditions
prescribed or recommended, and that has not been used to a material extent or for a material time.
“The rDNA construct in a GE animal that is intended to affect the structure or function of the
body of the GE animal, regardless of the intended use of products that may be produced by the
GE animal, meets the FFDCA drug definition,” the guidance states (on page 5). A new animal
drug is considered “unsafe”unless FDA has approved an application for that particular use, or it is
for investigational use and subject to an exemption from the drug approval requirement (among a
few other specified exemptions). Therefore, most developers will have to submit to the
“Investigational New Animal Drug” (INAD) process at FDA prior to shipping any GE animals or
to marketing any food or feed derived from GE animals. In other words, it is illegal to introduce
food from a GE animal into the food supply that has not been approved by FDA. The guidance
lays out the pre-market approval process including the information to be required of developers.
Under the guidance, FDA will examine both the direct toxicity (including allergenicity) potential
of food from a GE animal as well as any indirect toxicity. Generally, food and feed will be
considered safe if the composition of edible materials from the GE animal can be shown to be as
safe as from a non-GE animal. The labeling requirements for GE-derived foods would be the
same as for other foods: FDA has oversight over the labeling of seafood, dairy products, and
whole shell eggs, and USDA over the labeling of most meat, poultry, and egg products (see
below). More specifically, food from GE animals would not have to be so labeled, except when it
takes on a different character from its non-GE counterpart.

ǯǯȱȱȱȱǻǼȱ
Several USDA agencies, operating under a number of statutory authorities, also have at least
potential roles in the regulation of transgenic and cloned animals and their products. As several
critical reviews have indicated, USDA has not had a clearly spelled out policy in this area,
including whether it intends to exercise these authorities to regulate GE animals.15 USDA’s
Animal and Plant Health Inspection Service (APHIS) earlier had expressed its intention to
publish an advance notice of proposed rulemaking (ANPR) on GE animals, possibly in 2008.16
Instead, in concert with the FDA’s notice on its draft guidance, APHIS published, in the
September 19, 2008, Federal Register, a request for information from the public and scientists on
how GE animals might affect U.S. animal health. Comments were accepted until November 18,
2008, as they had been for the FDA draft guidance. Further APHIS action was pending in midJanuary 2009.
APHIS has broad authority, under the Animal Health Protection Act (AHPA; 7 U.S.C. §8301 et
seq.) to regulate animals and their movement to control the spread of diseases and pests to farmraised animals. APHIS also administers the Viruses, Serums, Toxins, Antitoxins, and Analogous
Products Act (21 U.S.C. §151-159), aimed at assuring the safety and effectiveness of animal
15

See, for example, Pew, Issues in Regulation. Beginning on p. 139, the report contains an extensive discussion on how
these and several other USDA authorities might be utilized for oversight of animal biotechnology.
16
APHIS in 2007 established an Animals Branch within its Biotechnology Regulatory Services “to develop a
regulatory framework for the possible regulation of genetically engineered animals.” Source: APHIS website,
“Regulation of Genetically Engineered Animals,” at http://www.aphis.usda.gov/biotechnology/
news_transgenic_animals.shtml.
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vaccines and other biological products, including those of GM origin, and the Animal Welfare Act
(7 U.S.C. §2131 et seq.), portions of which govern the humane treatment of several kinds of
warm-blooded animals used in research (but generally not agricultural animals). Elsewhere at
USDA, the Food Safety and Inspection Service (FSIS) is responsible for ensuring the safety and
proper labeling of most food animals and meat and related products derived from them under the
Federal Meat Inspection Act (21 U.S.C. §601 et seq.) and Poultry Products Inspection Act (21
U.S.C. §451 et seq.).

ȱȱ
Reports and studies have cited a number of other authorities and federal agencies that are or could
be relevant. The National Environmental Policy Act (NEPA; 42 U.S.C. §4321 et seq.) requires
federal agencies to consider the environmental impacts of their actions.17 The Environmental
Protection Agency derives its authority from, among other laws, the Federal Insecticide,
Fungicide and Rodenticide Act (FIFRA; 21 U.S.C. §301 et seq.); pesticides derived from living
organisms, including those of biotechnology, are within its purview. The Interior Department’s
Fish and Wildlife Service and the Commerce Department’s National Marine Fisheries Service
have also been cited.18

ȱ¢ȱȱ
In 1997, scientists at the Roslyn Institute in Scotland used nuclei from the mammary cells of an
adult sheep to clone “Dolly.” Such nuclear transfer (NT) techniques were first developed in
amphibians in the 1950s. They were first used in sheep in 1986, with the production of clones
using nuclei taken from sheep embryos. The significance of Dolly was that she was cloned from
differentiated cell types obtained from an adult (called “somatic cell nuclear transfer” or SCNT),
rather than undifferentiated cells from an embryo (“embryonic NT”).
Cloning in animal agriculture is generally not applied in isolation from other biotechnologies
such as genetic engineering. Scientists note that cloning does not require fertilization and is not,
by itself, a form of genetic engineering, i.e., altering, removing, or inserting genes into an
animal’s existing DNA. However, cloning can involve transgenic as well as non-transgenic cells.
SCNT is not yet a notably efficient technique ready for widespread commercial adoption. For
example, only about 6% of the embryos transferred to recipient cows resulted in healthy, longterm surviving clones, according to a 2005 report.19 The European Food Safety Authority (EFSA)
recently reported that overall success rates vary by species, ranging from 0.5% to 5%.20

17

The FDA guidance discusses how NEPA requirements will apply to the GE animal approval process.
The FDA guidance on GE animals states that the agency will work with other relevant federal and state agencies
should it receive a request for approval of a GE animal intended for release into the wild.
19
D. N. Wells, “Animal Cloning: Problems and Prospects,” Review of Science and Technology, 24(1): 251-264, 2005.
20
European Food Safety Authority. Draft Scientific Opinion on Food Safety, Animal Health and Welfare and
Environmental Impact of Animals Derived from Cloning by Somatic Cell Nucleus Transfer (SCNT) and their Offspring
and Products Obtained from the Animals, Enorsed for public consultation December 19, 2007 and released January 11,
2008. Hereinafter cited as EFSA draft scientific opinion. Accessed on the Internet at http://www.efsa.europa.eu/EFSA/
efsa_locale-1178620753812_1178676922939.htm.
18
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Success rates are said to be improving, however. As more efficient cloning technologies, which
can overcome the range of cloning abnormalities that have resulted from SCNT, are introduced,
they could provide new opportunities in human medicine, agriculture, and animal welfare. This is
the focus of much of the current international animal biotechnology research.
The EFSA draft scientific opinion estimated the number of live clones worldwide in 2007 to be
less than 4,000 cattle and 1,500 pigs, of which about 750 cattle and 10 pig clones were in the
United States. EFSA reported that life span data were limited, with only a few reports on cattle of
six to seven years of age and no data available in 2007 on the full natural life span of livestock
clones generally.21

ȱȱȱ
The FDA in July 2001 began asking companies to refrain voluntarily from marketing the products
of cloned animals and their offspring until it could fully assess the scientific information on their
safety. It subsequently issued two draft risk assessments on the matter, culminating in the release
of a final risk assessment—and industry guidance that effectively lifted its voluntary
moratorium—on January 15, 2008.

What Is Cloning?

Cloning, or somatic cell nuclear transfer, is a process by which animals are reproduced asexually.... In cloning, a
differentiated somatic cell (a non-germ line cell from an existing animal) is introduced to an oöcyte (a cell that is the
immediate precursor of a mature egg) that has had its nucleus (and thus its genome) removed, and then, following
some manipulations, is induced to start replicating. If all goes well, the dividing cell is implanted into a female animal
(dam), continues to develop normally, and is delivered just as any newborn.
—Animal Cloning: A Risk Assessment, p. 20

What’s the Difference Between a Cloned and a GE Animal?

Clones covered by FDA’s January 2008 risk assessment and guidance are “just clones”—that is, they are copies of
individual conventionally-bred animals, and do not contain any rDNA constructs. What can be confusing is that an
animal clone can be genetically engineered (i.e., have an rDNA construct introduced into it), and a GE animal can be
reproduced by cloning. The September 2008 guidance covers GE animals, regardless of whether they were
reproduced by cloning, but does not cover animal clones that do not contain an rDNA construct.
—Q and A to Accompany FDA’s September 18, 2008 Draft Guidance
Some stakeholders, including several Members of Congress, wanted a continuation of the
moratorium until more studies are completed on safety and other aspects of animal cloning. Their
views were reflected in nonbinding language to accompany the omnibus spending measure for
FY2008, which passed in late 2007, and binding language in the Senate version of the pending
farm bill (H.R. 2419); see “Congressional Action,” at the end of this report, for details.
In an October 2003 draft risk assessment, the FDA had concluded that “the current weight of
evidence suggests that there are no biological reasons ... to indicate that consumption of edible
products from clones of cattle, pigs, sheep or goats poses a greater risk than consumption of those
products from their non-clone counterparts.”22 However, shortly after the assessment’s
21
22

Ibid.
See http://www.fda.gov/cvm/Documents/CLRAES.pdf.

ȱȱȱ

şȱ

ȱ

¢ȱȱȱǱȱȱȱȱ ȱ

publication, many members of the FDA’s Veterinary Medicine Advisory Committee stated that
there were not enough data to fully understand any potential risks from this relatively new
technology.23
On December 28, 2006, the FDA’s CVM released another long-awaited risk assessment—also in
draft form, along with a proposed risk management plan and draft guidance for industry—on the
safety of animal clones and their offspring.24 The lengthy risk assessment examined two
important questions: the safety of food from cloned animals and their progeny, and the effects of
the process on the health of these animals. FDA officials stressed that the risk assessment did not
address any other issues, such as the social and ethical aspects of cloning or consumer acceptance
of cloned animal products. The risk assessment also focused only on cloning from non-transgenic
cells. This risk assessment is now final.25
The final risk assessment concluded—as had the December 26, 2006 draft—that the meat and
milk of clones of adult cattle, pigs, and goats, and the meat and milk from the offspring of these
clones, were as safe for human consumption as the food from conventionally bred animals. The
FDA added that not enough data were available to reach the same conclusions about sheep clones
(or other species) and recommended that they not yet be used for human food. The risk
assessment arrived at these conclusions after analyzing physiological, anatomical, health, and
behavioral data on the animals and evaluating available information on the chemical composition
of their milk and meat. FDA said its final assessment was peer-reviewed by an independent panel
of experts, who agreed with the findings. The final assessment also took into account many
thousands of public comments and additional data that became available since the draft was
prepared, the agency said.
The agency said it would not require any special measures (including labeling) relating to the use
of food products or animal feed derived from cloned cattle, goats, and pigs because they are “no
different from food derived from conventionally bred animals. Should a producer express a desire
for voluntary labeling (e.g., ‘this product is clone-free’), it will be considered on a case-by-case
basis to ensure compliance with statutory requirements that labeling be truthful and not
misleading.”26 The industry guidance states that products from the offspring of cloned animals of
any species are suitable for food or feed consumption.
Upon release of the 2006 proposed assessment, FDA officials said they were continuing to ask
livestock breeders and producers to keep food products from cloned animals and their offspring
out of commerce. This moratorium was announced in July 2001 and remained in effect until the
final guidance was released in January 2008. Although the FDA moratorium is no longer in
effect, USDA has since been encouraging technology providers to maintain the voluntary
moratorium, but for products from cloned animals only. Food products from cloned animals’
offspring would not be similarly constrained. During a continuation of this moratorium, USDA

23

“Panel Calls for More Data on Animal Cloning Risks,” Food Chemical News, November 10, 2003.
Availability of the draft documents was formally published in the January 3, 2007, Federal Register (72 FR 135-137;
FDA docket no. 2003N-0573); comments were accepted until May 3, 2007.
25
FDA documents were posted on the Internet at http://www.fda.gov/cvm/cloning.htm on January 15, 2008. They are
the Risk Assessment, Risk Management Plan, and Guidance for Industry.
26
“FDA Issues Documents on the Safety of Food from Animal Clones,” FDA press release, January 15, 2008.
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said it would “work closely with stakeholders to ensure a smooth and seamless transition into the
marketplace for these products.”27
Officials emphasized that, at least initially, almost all cloning-related foods will come not from
the clones themselves but rather from their sexually reproduced offspring. Cloned animals—like
other “elite” breeding animals such as a prized bull—are too valuable to use for food production,
except possibly when they reach the end of their productive lives. The FDA observed that it can
cost $20,000 or more to produce one such animal.
One ongoing question has been whether, in fact, milk and meat from the offspring of clones are
entering the food supply. Several press accounts have quoted farmers and others who say they
have sold such offspring to be slaughtered for food, and that the total number nationwide may be
in the hundreds or even thousands. On the other hand, those numbers would amount to a small
fraction of the total number of U.S. livestock slaughtered (e.g., 34 million cattle and 109 million
hogs in 2007).28
FDA’s January 2008 risk assessment did conclude that some animals involved in cloning (notably
cattle and sheep surrogate dams) and some clones are at greater health risk than conventional
animals. While the types of animal health problems observed in cloned animals are no different
than those found with other assisted reproductive technologies, these problems appear more
frequently in cloning than in the other technologies. Such problems include late gestational
complications in the surrogate mothers, and increased risk of mortality and morbidity in calf and
lamb clones that are apparently caused mainly by large offspring syndrome (LOS). Swine and
goat clones and their mothers do not appear to experience any additional cloning-related
problems, FDA reported.
FDA found that livestock clones as a group tend to have more health problems and death rates at
or right after birth. However, the risk assessment added that most animals surviving the neonatal
period appear to grow and develop normally, and that no increased risk of adverse health effects
have been reported in clones approaching reproductive maturity. The agency said that the
technology was too new to draw any conclusions on the relative longevity of livestock clones.

ȱ ȱ
Cloning currently is not in commercial use in Europe, nor is there any specific authorization
procedure in the European Union for products from cloned animals.29 The European Food Safety
Authority (EFSA) on July 24, 2008, released its scientific opinion on the food safety, animal
health and welfare, and environmental impacts of animals derived from cloning. The EFSA
opinion was limited to cattle and pigs, but its findings generally do not appear to be substantially
different from those in the FDA assessment. According to EFSA, “Based on current knowledge,
and considering the fact that the primary DNA sequence is unchanged in clones, there is no
indication that differences exist in terms of food safety between food products from healthy cattle
and pig clones and their progeny, compared with those from healthy conventionally-bred
27

Statement by Bruce Knight, Under Secretary for Marketing and Regulatory Programs on FDA Risk Assessment on
Animal Clones, January 15, 2008.
28
See, for example, “Animal Clones’ Offspring Are in Food Supply,” The Wall Street Journal online, September 2,
2008.
29
“EFSA launches its draft opinion on animal cloning for public consultation,” EFSA press release, January 11, 2008.
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animals.” As with FDA, the EFSA conclusion is based on an examination of compositional and
nutritional data, the probability for the presence of novel constituents, the health status of the
animal, and available data on toxicity, allergenicity, and microbiology.
EFSA agreed that SCNT can be a successful reproductive technique, although death and disease
rates of clones are significantly higher than those of conventionally reproduced animals. EFSA
noted that surrogate dams have higher rates of failed pregnancies and other problems. “A
significant proportion of clones, mainly within the juvenile period for bovines and perinatal
period for pigs, has been found to be adversely affected, often severely and with fatal outcome.
Most clones that survive the perinatal period are normal and healthy,” however. Adverse health
effects were not observed in the offspring of clones, although studies have not been conducted for
their entire lifespans.30
EFSA also found no indication of new or additional environmental risks compared with
conventionally bred animals.
The EFSA report findings are being used by the European Commission (EC), the European
Parliament, and member states as they discuss their policies regarding animal cloning. There is
disagreement over the issue among officials in the various European bodies. This was illustrated
when the European Parliament in early September 2008 approved a resolution asking the EC to
propose a comprehensive ban on cloning animals for food, out of animal health and welfare and
ethical concerns.31 However, at an initial discussion of the issue in early January 2009, EC
commissioners indicated that there was time to consider a science-based risk assessment before
deciding whether or not to ban cloning.32

ȱ ȱ
Critics, including a number of consumer advocacy and animal rights groups, oppose the use of
cloned animals and their offspring for food. In October 2006, a coalition formally petitioned the
FDA to impose a moratorium on producing foods from cloned animals, and to establish rules for
mandatory pre-market review and approval of cloned foods by regulating clones as new drugs
under the food and drug act. These consumer and animal welfare groups contend that FDA has
ignored or minimized a number of food safety and animal welfare problems. These include the
treatment of surrogate mothers with high doses of hormones and their clone offspring, who often
have severely compromised immune systems, with large doses of antibiotics, which could enter
the human food supply; imbalances in clones’ hormone, protein, or fat levels that could
compromise meat and milk safety and quality; the possibility of increased foodborne illnesses;
and a wide variety of health problems and abnormalities in the animals themselves. Consumer
advocates assert that there are no consumer benefits from cloning.
FDA disagrees, citing the potential to breed livestock that meet consumers’ changing tastes for
traits like leanness, tenderness, color, size of meat cuts, and so forth. These would be in addition
30

“Scientific Opinion of the Scientific Committee on a request from the European Commission on Food Safety,
Animal Health and Welfare and Environmental Impact of Animals derived from Cloning by Somatic Cell Nucleus
Transfer (SCNT) and their Offspring and Products Obtained from those Animals,” The EFSA Journal (2008) 767, 1-49;
http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902019540.htm.
31
“European Parliament urges ban on cloning for food,” Food Chemical News, September 8, 2008.
32
“EU not ready to ban animal cloning for food,” Food Chemical News, January 19, 2009.
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to potential producer-related benefits such as disease resistance, climate suitability, fertility, and
improved physical qualities, FDA states.33
Opinion polls have suggested that the general public may not yet be ready for widespread animal
cloning. A 2006 poll commissioned by the Pew Initiative on Food and Biotechnology, for
example, found that Americans generally were not well informed about animal cloning, but 64%
of those questioned are “uncomfortable” with it. Forty-three percent of Americans believed that
foods from clones are unsafe, the survey found. Cloning opponents cite these types of findings to
argue that products from cloned animals should be labeled so that consumers could avoid them if
they wanted to. Some critics have urged the President to halt all FDA actions on cloning until a
national panel that includes ethicists and religious leaders can consider the ethical and other social
issues that they believe the technology has raised.
The NRC animal biotechnology report had stated that embryonic splitting and nuclear transfer
using embryonic (not adult) cells were performed with some dairy cows to successfully produce
genetically valuable offspring that were milked commercially and whose milk and meat did enter
the food supply. Few concerns were raised by NRC authors about using these types of cloned
animals for food, since they are generally believed to pose a low level of food safety concern.
However, evaluating cloned-animal food composition “would be prudent to minimize any food
safety concerns. The products of offspring of cloned animals were regarded as posing no food
safety concern because they are the result of natural matings.”34 Other issues, notably consumer
acceptance, social values, and animal welfare, could eventually overshadow any lingering
questions about human health.

ȱ¢ȱȱ
The following are among the policy concerns that have arisen along with the development of new
biotechnologies in animal agriculture. Some may be more applicable to GE-related technologies
than to cloning per se, although others, like social acceptance and animal welfare concerns, may
apply to both.

ȱ ȱ
Environmental concerns arising from emerging animal biotechnologies are largely speculative at
this time because few products have been commercialized. For example, although the EFSA draft
scientific opinion foresaw no environmental impact, it also noted that limited data were available
on this aspect of animal cloning.
Industrial developers of agricultural biotechnology might argue that more efficient production of
animal-based feeds could reduce the resources necessary to produce food and, thereby, reduce the
environmental burden of animal production. Should the development and widespread adoption of
the “EnviroPig” (tm), which produces less phosphorus in its waste, occur, it might be considered
by some to be a positive environmental benefit of agricultural biotechnology.

33
34

“A Primer on Cloning and Its Use in Livestock Operations,” at http://www.fda.gov/cvm/CloningRA_Primer.htm.
CAST, Animal Agriculture, p. 8.
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The 2002 NRC animal biotechnology report noted potential negative environmental impacts of
genetically altered animals. Escape, survival, and gene flow into wild populations were identified
as major concerns. Of most concern to the NRC committee was the escape into the environment
of “super” salmon that have been genetically modified for rapid growth, and the likelihood that
they could then breed with wild populations in the environment.35 Other genetically altered
animals such as fish, insects, and shellfish could also potentially escape into natural environments
and become feral, disrupt ecosystems, or introduce novel genes in a natural population.
The FDA guidance on GE animals notes that the agency will comply with requirements of the
National Environmental Policy Act (NEPA). Environmental risks are likely to differ depending
upon the animal and application. For example, the types of environmental concerns arising from a
GE cow bred for resistance to mastitis will differ greatly from the concerns raised by a GE freshwater fish engineered to grow more rapidly.36 Material to accompany the FDA’s final guidance
notes that “although the agency has extensive experience in environmental assessment, including
for fish, other federal and state agencies have overlapping or complementary authority and
expertise” that FDA intends to tap. It also promised to make the results of environmental reviews
public.37

ȱ¢ȱ
Unexpected and unintended compositional changes arise with all forms of plant and animal
genetic modification, including GE, concluded the IOM-NRC report on genetically engineered
foods.38 The report added that, so far, no GE-related adverse human health effects have been
documented. However, the report’s authors cited “sizeable gaps” in the ability to identify
compositional changes caused by all forms of genetic modification—whether GE or
conventional—and their relevance for human health, and they recommended new approaches for
assessing the safety of new foods both before and after they enter the market.
Previous research and experience with commercializing transgenic plants suggested that negative
effects on human health were virtually nonexistent. While not asserting that genetically modified
organisms necessarily generate health problems, more recently reported research in peer-reviewed
scientific journals has suggested that GMOs may raise food safety concerns:
•

Australian researchers have published an article explaining that the transfer from
a bean to a pea gene that expresses an insecticide protein has resulted in antibody
production in mice fed the transgenic pea. The antibody reaction is a marker of
allergic reaction.39

•

Italian researchers at the University of Urbino had previously shown that
absorption of transgenic soy by mice induced modifications in the nuclei of their

35

NRC, Animal Biotechnology, p. 73.
FDA, Consumers Q&A, accompanying its September 18, 2008, draft guidance.
37
“FDA’s Response to Public Comments,” accessed January 21, 2008, at http://www.fda.gov/cvm/
GEanimals.htm#Consumer%20Health%20Information.
38
IOM-NRC, Safety of Genetically Engineered Food, p. 1.
39
V. E. Prescott, P. M. Campbell, et al., “Transgenic Expression of Bean-Amylase Inhibitor in Peas Results in Altered
Structure and Immunogenicity,” Journal of Agriculture and Food Chemistry, 53(23); 9023-9030, November 2005.
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liver cells. Recent research showed that a return to non-transgenic soy made the
observed differences disappear.40
•

Norwegian scientists at the University of Tromso demonstrated that the catalyst
35S CaMV, an element of the genetic structures used to modify a plant, can
provoke gene expression in cultured human cells. This catalyst was previously
believed to operate in this way only in plants.41

In the NRC animal biotechnology report, experts observed that the scientific principles for
assessing the safety of GE animals are “qualitatively the same” as for non-GE animals.42
However, because GE can introduce new proteins into foods, the potential for allergenicity,
bioactivity, and/or toxicity responses should be considered, they said. Others have remarked that
animals genetically engineered for nonfood products like pharmaceuticals or replacement organs
might be of concern if such animals entered or affected the food supply.

ȱȱȱȱ
Criteria for selecting desirable traits to be produced through transgenic animals will likely be
based on the demand for specific commercial characteristics. Even if scientific evidence is
convincing that GE and cloned animal products are safe and beneficial for human consumption or
economically valuable to producers, other concerns may limit marketplace and consumer
acceptance.
Polls in recent years in the United States indicate that public knowledge about food and
biotechnology generally remains limited. In two 2005 surveys, approximately half of those
surveyed expressed opposition to the use of biotechnology in the food supply.43 More than half of
those in a 2005 Pew-sponsored poll said they opposed research into genetically modified animals,
although opposition declined with increased knowledge. Many Americans have heard about
animal cloning; two-thirds expressed discomfort with it—more of them out of religious or ethical
concerns than food safety concerns. A majority of respondents to the Pew survey believe that
regulators should take into account ethical and moral considerations. (See also the 2006 Pew
findings on cloning, under “Cloning Policy Developments,” section on “Other Views.”)
Consumers may be less willing to accept the practice of genetically modifying animals than
plants, some have argued, observing that people relate differently to animals, which many
recognize as sentient beings. Some observers have expressed the concern that cloning farm
animals might lead more quickly to human and pet cloning, which those observers oppose. Others
believe that modifying animals, for example, to save human lives through xenotransplantation or
the production of some important drug, might be more acceptable than doing so simply to
produce more or cheaper food.

40
M. Malatesta, C. Tiberi, et al., “Reversibility of Hepatocyte Nuclear Modifications in Mice Fed on Genetically
Modified Soybean,” European Journal of Histochemistry, 49(2):237-242, July-September 2005.
41
M. R. Myhre, K. Fenton, et al., “The 35S CaMV Plant Virus Promoter Is Active in Human Enterocyte-like Cells,”
European Food Research and Technology, 222(1-2):185-193, January 2006.
42
NRC, Animal Biotechnology, p. 65.
43
Gallup poll on biotechnology and food safety, July 2005; Mellman Group/Public Opinion Strategies Poll Conducted
for the Pew Initiative on Food and Biotechnology, October 2005. See http://www.pewagbiotech.org (accessed March
20, 2006).
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Further, science alone cannot resolve ethical views that appear to vary widely:
Some people, irrespective of the application of technology, consider genetic engineering of
animals fundamentally unethical. Others, however, hold that the ethical significance of
animal biotechnologies must derive from the risk and benefits to people, the animals, and/or
the environment. Yet another view focuses on the right of humans to know what they are
eating or how their food or pharmaceuticals are being produced and therefore labeling
becomes an issue to be addressed.44

Food industry leaders appear sensitive to consumer unease with animal biotechnology in general
and cloning in particular. Many companies are not yet ready to process and sell meat and milk
from transgenic and cloned animals because, they believe, consumers may view the products as
less safe than more conventionally produced food products. The food industry also does not want
to be portrayed as overstepping any widely held ethical or moral concerns about the new
technologies.45
Such observations led some skeptics of animal biotechnology to propose that the FDA not only
consider the science and safety issues, but also these broader concerns. In the area of human
reproductive health, for example, the FDA and other federal agencies have invoked particular
moral arguments either to reinforce scientific arguments or to counterbalance scientific evidence.
Others believe that the FDA should base its decisions only on scientific evidence, and perhaps
some other body should be established to consider the ethical and cultural questions. As the NRC
animal biotechnology report observed, regulatory decisions and enforcement involving animal
biotechnology “are difficult in the absence of an ethical framework.”46

ȱ
Some believe that segregating and labeling the products of biotechnology in agriculture,
including meat and milk, would enable the consumer to choose whether or not to buy such
products. Either segregating and labeling biotechnology products or failing to do so could
contribute to public suspicion that these products are flawed or different in some negative way,
which may lead to contradictory policy decisions.47 As noted, the FDA guidance on GE animals
does not require their products to be so labeled. Opponents of labeling argue that biotechnology
products essentially are the same as more conventional products—and are subjected to the same
rigorous safety standards—and therefore should be treated no differently in the marketplace. A
study by USDA’s Economic Research Service reported that consumers’ willingness to pay for a
food item declines when the food label indicates that it was produced with the aid of
biotechnology.48

44

NRC, Animal Biotechnology, p. 13.
These concerns were explored in depth at an October 2006 symposium, “Animal Biotechnology: Considering Ethical
Issues,” sponsored by the Pew Initiative on Food and Biotechnology and by Michigan State University. Also reported
by Food Chemical News, October 23, 2006.
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In December 2007, two leading U.S. livestock cloning companies announced they were creating a
voluntary system for tracking cloned animals. The program, which they asserted “is designed to
facilitate marketing claims,” is to involve a national registry providing for the individual
identification of each cloned animal, affidavits that owners will sign committing to proper
marketing and disposal of such animals, and monetary deposits to be returned when such
commitments are fulfilled. Consumer organizations immediately criticized the initiative, noting
that it would not track the offspring of cloned animals and was not mandatory.49
However, fierce debate continues regarding even the voluntary labeling of products to denote that
they are not derived from biotechnology—notably the use of so-called “rBST-free” labels on
dairy products. Although FDA cleared rBST as safe for commercial use in 1994, and it has been
widely adopted by U.S. dairy farmers, the substance continues to be viewed skeptically by some
consumer advocates. They have convinced a number of dairy processors and retailers to label
their products as free of added BST manufactured through the use of recombinant DNA
technology. FDA guidance permits such labeling so long as it is not misleading, is presented in
the proper context, and is adequately substantiated. For example, a firm cannot state that its
product is “BST-free” because the substance occurs naturally in milk, or even simply that it is
“rBST-free” because that could imply a compositional difference between naturally occurring and
rBST, which there is not, FDA has ruled. But certain claims that no rBST was used could be
acceptable, the agency stated.50
FDA has looked to the states to evaluate the acceptability of such labels, and a number of these
states have challenged processors’ use of them. Battles over such restrictions have been notable in
Pennsylvania, Ohio, Utah, Kansas, and elsewhere.51
Meanwhile, USDA has reminded stakeholders that products from cloned animals are not eligible
to be labeled as organic, under its National Organic Program (NOP). While cautioning that the
organics program is a marketing, not a food safety, program, USDA also noted: “Cloning as a
production method is incompatible with the Organic Foods Production Act and is prohibited
under the NOP regulations.”52 However, the status of products from clone offspring is less clear.
The Department noted that USDA’s Agricultural Marketing Service, where the NOP is located,
was preparing rulemaking to address the organic status of such offspring.53

ȱȱ
Some aspects of gene transfer, and of cloning, have the potential to create infectious disease
hazards and/or impaired reproduction. Looming large in the ethical debate are questions about
whether genetic modifications, cloning, and other technologies stress animals unnecessarily,
49
Sources: “Top U.S. Cloning Companies Announce New System to Track Cloned, Livestock,” December 19, 2007,
Viagen press release, and “Consumer Groups Displeased with Voluntary Animal Clone Registry,” FDA Week,
December 21, 2007.
50
FDA, “Interim Guidance on the Voluntary Labeling of Milk and Milk Products From Cows That Have Not Been
Treated With Recombinant Bovine Somatotropin,” Federal Register, February 10, 1994.
51
See, for example, “Dairy processors fight to save ‘rBST-free’ labels, March 3, 2008, and “Kansas is latest
battleground in ‘rBST-free’ labeling fight,” December 22, 2008, both in Food Chemical News.
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subject them to higher rates of disease and injury, and hasten death.54 The NRC animal agriculture
report noted, for example, that ruminants produced by in vitro culture or nuclear cell transfer
methods tend to have higher birth weights and longer gestation periods than those produced by
artificial insemination, creating potential calving problems. Nuclear transfer techniques to
propagate genetic modifications may increase risks to the reproductive health and welfare of both
the surrogate female animals and their transgenic offspring. The report cited other evidence of
problems such as anatomical, physiological, or behavioral abnormalities in many transgenic
animals.55 Some scientists have countered that animal welfare problems have been exaggerated
and tend to recede, particularly as the technologies are perfected. Most appear to agree, however,
that animals originating from some forms of genetic modification or from cloning may require
closer observation and care. (See also the section of this report on Cloning Policy Developments.)
In Europe, officials continue to consider the ethical dimensions of animal welfare in formulating
their own cloning policies. The EC charged a separate panel, the European Group on Ethics in
Science and New Technologies, with drafting an opinion. This group released an opinion on
January 16, 2008, stating, in part:
Considering the current level of suffering and health problems of surrogate dams and animal
clones, the EGE has doubts as to whether cloning animals for food supply is ethically
justified. Whether this applies also to progeny is open to further scientific research. At
present, the EGE does not see convincing arguments to justify the production of food from
clones and their offspring.

If such products were to be allowed into the market, certain requirements regarding food safety,
animal welfare and traceability should be met, the group added.56

ȱ¢ȱ
Could the introduction of a few genetically altered or cloned “superspecies” bring too much
genetic uniformity to herds? As genetic diversity declines, herds could be more susceptible to
diseases, leading to large production losses and/or much heavier use of antibiotics and other
animal drugs to treat them, some have argued. A related concern is that a relative handful of
“elite” producers or breeders might hold the proprietary rights to these species, to the
disadvantage of many farmers and ranchers. Some animal biotechnology researchers have pointed
to the potential importance of preserving unaltered germlines in domestic animals because they
could prove to be an invaluable “gene bank” in the event that novel infectious diseases or
inheritable genetic defects were inadvertently introduced into modified subpopulations as a
consequence of genetic modification.

54
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If the United States were to be the first country to approve food products from cloned animals,
how might the decision affect U.S. exports? Any exports of the products of animal biotechnology
would presumably encounter a wide spectrum of foreign regulatory regimes, some more
restrictive than the U.S. system. For example, the current European Union restriction on new
biotechnology products is likely to encompass various restrictions on animal biotechnology as it
does on plant biotechnology. On the other hand, researchers in a number of other countries,
including some EU members, have been producing clones, and one—France—has published its
own risk assessment on clones that, FDA has observed, generally agrees with the U.S.
assessment.57
International guidelines pertaining to exports of animal products derived from biotechnology are
being considered. The Codex Ad Hoc Intergovernmental Task Force on Foods Derived from
Biotechnology held an initial meeting in September 2005 in Chiba, Japan, to determine the new
work projects. Almost every country, except for the United States, proposed an animal
biotechnology project. The task force agreed to move forward with a recombinant DNA (r-DNA)
animal project, specifically to develop guidelines for how countries would assess the safety of
foods derived from r-DNA animals.58 At a meeting in November-December 2006 in Chiba, the
task force, among other things, reviewed the developing guidelines, agreeing to limit their scope
to food safety and nutritional issues (while recognizing the importance of others like animal
welfare, environmental, and ethical concerns).59
USDA has said it would consider “discussion with industry on possible verification of its supply
chain management plan to ensure that trading partners are aware of whether or not they receive
cloned or non-cloned products.”60
Imports of GE animals and their products into the United States also are of concern to some. In a
December 2008 audit report, USDA’s Office of Inspector General (OIG) concluded that the
Department has not established an import control policy for such imports but needs to do so. “To
mitigate any risks to the U.S. environment, agriculture, and commerce from unapproved
transgenic plants and animals entering the U.S. food supply, USDA will need to monitor” foreign
developments in such technologies more closely, OIG also noted.61
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Stephen F. Sundlof, then Director of FDA Center for Veterinary Medicine, transcript of a December 28, 2006,
teleconference on the draft risk assessment.
58
Codex is recognized by the World Trade Organization (WTO) as the body that sets food safety standards for
facilitating international trade of food products. The WTO cites Codex texts as a benchmark in the Agreement on
Sanitary and Phytosanitary Measures (SPS).
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The collaborative document is entitled Proposed Draft Guideline for the Conduct of Food Safety Assessment of
Foods Derived from Recombinant-DNA Animals. Codex adopted the guidelines at its Geneva meeting on June 30-July
5, 2008.
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Questions and Answers, FDA’s Final Risk Assessment, Management Plan and Industry Guidance on Animal Clones
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USDA, OIG, United States Department of Agriculture Controls Over Importation of Transgenic Plants and Animals,
Audit Report No. 50601-17-Te, December 2008.
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Members of Congress in the past have proposed various bills aimed at more closely regulating the
plant and animal products of agricultural biotechnology generally, requiring such products to be
labeled, and providing a means to recover any damages caused by the technology. As with human
cloning, ethical issues concerning animal clones and other animal biotechnologies also may
continue to be visible public issues. As before, the 111th Congress could be asked to play a larger
role in weighing the benefits and costs of these evolving technologies, and to refine existing
government oversight.
In the 110th Congress, the Senate-passed version of the 2007-2008 farm bill (H.R. 2419, in
Section 7507) contained statutory language that would have required the FDA both to postpone
publication of its final risk assessment until the completion of several newly mandated studies,
and also to maintain the voluntary marketing moratorium until then. However, conferees deleted
the Senate language from the final measure (signed into law as P.L. 110-234).
More specifically, the Senate bill would have directed the HHS Secretary to contract with the
National Academy of Sciences to conduct a study on the safety of food products from cloned
animals and the health effects and costs attributable to milk from cloned animals, with a report to
Congress due within one year of enactment. The study was to address whether there were a
sufficient number of studies to support the FDA draft assessment, and whether there were other
pertinent ones that were not taken into account. It would have included an evaluation of potential
public health effects and associated health care costs, and an evaluation of any consumer behavior
and negative health and nutrition impacts resulting from a decrease in dairy consumption if milk
from cloned animals and their offspring is commercialized.
Animal cloning-related bills (S. 414 and H.R. 992) were introduced in early 2007, both of which
would have amended federal food safety laws to require that foods from cloned animals and their
offspring be so labeled. Also introduced in early 2007 was S. 536/H.R. 1396, which would have
prohibited the use of the “organic” label on food products from cloned livestock or their
offspring. Another (H.R. 4855), introduced in late 2007, would have required studies like those in
the Senate farm bill on the impacts of food products from cloned animals entering the food
supply.
In late July 2008, three related bills were introduced that, their sponsor said, were to create a
comprehensive framework for regulating GMOs. H.R. 6636 would have required the labeling of
all foods produced with GE material. H.R. 6635 would have prescribed relatively stringent new
regulations for FDA approval and oversight of GE crops. H.R. 6637 would have regulated
business dealings between agricultural producers and the developers of genetically engineered
plants and animals, and sought to hold biotechnology companies liable for any adverse on-farm
impacts from their products.
Although these bills were not enacted, they could re-emerge, along with others, in the 111th
Congress.

ȱȱȱ

ŘŖȱ

¢ȱȱȱǱȱȱȱȱ ȱ
ȱ

ȱȱ ȱ
Geoffrey S. Becker
Specialist in Agricultural Policy
gbecker@crs.loc.gov, 7-7287

ȱȱȱ

Tadlock Cowan
Analyst in Natural Resources and Rural
Development
tcowan@crs.loc.gov, 7-7600

Řŗȱ

